Protagonist Therapeutics (PTGX) drew investor attention after reporting strong Phase 2b results for its drug icotrokinra. This development led Johnson & Johnson to launch Phase 3 trials for ulcerative colitis and Crohn's disease. The updates point to meaningful pipeline momentum.

The excitement around Protagonist Therapeutics has fueled real momentum in its stock, with a 17.7% one-month share price return and an impressive 96.7% gain year to date. While recent pipeline wins are fresh, the 61.1% total shareholder return over the past year shows that both short-term and long-term investors are being rewarded as optimism builds for icotrokinra’s future.

If you’re interested in discovering more promising companies in the pharma space, now is the ideal moment to explore See the full list for free.

With shares surging and clinical wins stacking up, the key question now is whether Protagonist Therapeutics is still undervalued or if the rapid price gains mean future growth is already reflected in the stock. Does this spell a genuine buying opportunity, or is the market getting ahead of itself?

Price-to-Earnings of 91.7x: Is it justified?

Protagonist Therapeutics is currently trading at a price-to-earnings (P/E) ratio of 91.7x, which is significantly higher than both the broader biotech industry and its peer group. With the last close at $76.69, the valuation raises important questions about whether the market is prematurely pricing in future growth or simply rewarding recent pipeline successes.

The price-to-earnings ratio measures what investors are willing to pay today for a dollar of the company’s current earnings. In biotech, high P/E ratios often reflect expectations for breakthrough products or strong earnings growth. However, they can also indicate an overheated market sentiment.

At 91.7x, Protagonist Therapeutics is priced much higher than the US Biotechs industry average of 17.9x and the average for its peers at 43.7x. Even when compared to the estimated fair P/E ratio of 33x, the current multiple stands out as especially elevated. If the market adjusts its optimism, it could move closer to this fair value benchmark in the future.

Result: Price-to-Earnings of 91.7x (OVERVALUED)

However, future success depends on continued clinical progress and the ability to avoid regulatory setbacks, which remain inherent risks in high-growth biotech stories like Protagonist's.

Another View: What Does Our DCF Model Say?

While the P/E ratio suggests Protagonist Therapeutics is trading at a premium, our SWS DCF model takes a long-term cash flow perspective and arrives at a strikingly different conclusion. According to this method, the stock is trading 71% below its estimated fair value, which signals considerable upside potential if forecasts hold true.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Protagonist Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 848 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own Protagonist Therapeutics Narrative

Feel free to dig into the numbers and build your own perspective, since anyone can create a personalized outlook for Protagonist Therapeutics in just a few minutes. Do it your way

A great starting point for your Protagonist Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

Don’t let valuable opportunities pass you by. Unlock a wealth of investment themes using the Simply Wall Street Screener and get ahead of the market today.

• Supercharge your portfolio with potential by checking out these 3583 penny stocks with strong financials that excel through financial strength and rapid growth stories.
• Capitalize on the AI revolution by targeting emerging winners with these 26 AI penny stocks at the forefront of artificial intelligence innovation.
• Secure reliable income streams for the future with these 21 dividend stocks with yields > 3% delivering compelling yields above 3%.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.